Switching to long-acting CAB/RPV was not linked to HBV reactivation or incident infection and may be a safe therapeutic option for most patients with HIV.
Despite these constraints, the investigators concluded that the results reinforce current perinatal HIV treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results